Introduction {#Sec1}
============

Although inborn errors of amino acid metabolism (IEM) are treatable disorders, long-term cognitive and behavioral problems are almost constant in patients despite strict dietary management and other treatment approaches. Factors underlying brain dysfunction are not fully understood.

Urea cycle disorders (UCDs, OMIM \#311250) are IEM characterized by recurrent hyperammonemic episodes, due to dysfunctions in any of the urea cycle pathway enzymes, a detoxification system that converts ammonia into urea. In the brain, astrocytes are responsible for detoxifying ammonia through glutamine synthetase (GS) and the amidation of glutamate to glutamine^[@CR1],[@CR2]^. Severe enzyme defects usually manifest symptoms during the first days of life, while symptoms of partial defects tend to appear later in life. Hyperammonemia can damage cerebral tissue by altering cerebral energy metabolism, glutamine/glutamate levels, neurotransmission, and signal transduction of pathways related to neuronal survival and plasticity^[@CR3],[@CR4]^. Neurocognitive dysfunctions and behavioral impairment represent common long-term outcomes that are likely to reflect chronic ammonia/glutamine toxicity^[@CR5],[@CR6]^.

Maple syrup urine disease (MSUD; OMIM \#248600) is caused by the deficiency of branched-chain α-keto acid dehydrogenase (BCKD) complex activity, a key enzyme for the amino acid catabolism, leading to increased levels of branched-chain amino acids (BCAAs) and their corresponding α-ketoacids^[@CR7]^. The BCKD complex is composed of three catalytic components: E1, E2 and E3 and two regulatory enzymes, the BCKD kinase (BCKDK) and BCKD phosphatase (PP2Cm)^[@CR8]^. Mutations in BCKDK (OMIM \#614923) are associated with decreased levels of BCAAs, epilepsy, intellectual disability and autism^[@CR9]^.

Patients with the most severe form of MSUD develop metabolic decompensation and encephalopathy within the first weeks of life and die if untreated^[@CR7],[@CR10],[@CR11]^. Therapy is based on strict dietary management with low BCAAs (mainly leucine) content and/or liver transplantation^[@CR12],[@CR13]^. Despite treatment, several studies have described small reductions in the intelligence quotient and increased rate of neuropsychiatric conditions, mainly attention deficit hyperactivity disorder (ADHD), depression and anxiety^[@CR14]--[@CR18]^. Neurotoxicity of BCAAs and their α-ketoacids, mainly leucine, might underlie neuropsychiatric disorders, as leucine plasma concentrations are closely correlated with acute symptoms^[@CR17]^. Due to blood-brain barrier (BBB) amino acid transporter saturation, increased BCAAs and α-ketoacids in the brain, are concomitant with deficiency of essential amino acids, causing brain-specific deficits in protein synthesis, neurotransmitter depletion and inhibition of mitochondrial enzymes^[@CR8],[@CR19]^.

Early detection and treatment is the gold standard to avoid long-term disabilities in IEM patients. Therefore, there is a need to find new biomarkers of neural function for the identification and management of those children that, despite metabolic management, are at risk to develop neurologic, cognitive and behavioral problems.

One currently accepted biomarker candidate for brain functioning is brain-derived neurotrophic factor (BDNF), as BDNF signaling is involved in brain development, synaptic function and plasticity^[@CR20]^. Activity-dependent regulation of BDNF expression is in part mediated by transcription factor methyl-CpG binding protein 2 (MeCP2), and altered levels of MeCP2, BDNF or their downstream signaling are widely implicated in neuropsychiatric diseases and mood disorders^[@CR21],[@CR22]^. Altered BDNF levels in plasma have been recently described in MSUD patients and the hippocampus of hyperammonemic rats^[@CR23],[@CR24]^. BDNF is also involved in glucose and energy homeostasis through control of energy intake and expenditure^[@CR25]^, in part by regulation of miRNA and protein synthesis through LIN28A RNA-binding protein^[@CR26],[@CR27]^. Additional candidate biomarkers are CACNA2D1-2 genes, which codify for α2δ1-2 regulatory subunits of the voltage-gated calcium channels (VGCCs)^[@CR28]^. Aside from its modulatory channel function, α2δ1-2 are essential for the formation and stabilization of new synapses by binding to oligomeric extracellular matrix glycoproteins thrombospondins (TSPs), which are codified by THBS genes^[@CR29]^. L-leucine and L-isoleucine are also well-known ligands of α2δ1-2 subunits^[@CR30]^ and have been postulated as necessary for their correct function^[@CR31],[@CR32]^.

Therefore, to gain insight into the molecular mechanisms underlying neurological deficits in IEM patients, we analyzed in peripheral whole blood the mRNA expression of a group of genes involved in brain development and synaptic function (*ADORA2A*, *CACNA2D2*, *FMR1*, *IRAK1*, *LIN28A*, *PTEN*, *MECP2 E1/E2*, *THBS1*, *THBS3*) in a cohort patients affected by UCD, MSUD and BCKDK deficiency. Gene expression in blood was correlated with AAs profile, BDNF protein levels in plasma, and neuropsychological symptoms, in an attempt to identify specific molecular pathways altered in each disorder, as well as common mechanisms underlying the pathophysiology of the neurological impairment present in different IEMs.

Results {#Sec2}
=======

Clinical information of patients {#Sec3}
--------------------------------

Table [1](#Tab1){ref-type="table"} shows a summary of clinical data and Table [2](#Tab2){ref-type="table"} shows treatment details and historical biochemical parameters of IEM patients included in this study.Table 1Summary of clinical characteristics, disease onset and outcome of IEM patients.PatientSexDisorderDefectAge at\
onsetSymptoms at onsetAge at blood analysisNPSY tests\
(evaluative age)Intellectual DisabilityPsychomotor delayExecutive function/\
attention deficitsOther Behavioral symptoms1MUCDOTC(\^)Asymptomatic16 yNO (\*)NONONONO2MUCDOTC9 dLethargy, failure to thrive10 yYES(7, 11 y)NO(IQ: 120)NOADHDAutistic traits3MUCDOTC8 ySeizures, learning difficulties19 yYES(13 y)NO(IQ: 88)NOVerbal, visual and working memory deficitsMood disorder, depression4FUCDOTC---Asymptomatic36 yNO (\*)NONONONO5MUCDHHH20 mMild psychomotor delay, lower limb pyramidal signs12 yYES(7 y)YES(IQ: 76)YESADHD,inhibition and literacy affectedNO6MUCDASL3 yLanguage delay13 yYES(7 y)YES(IQ: 54)YESVerbal, attention and working memory deficitsLanguage and verbal comprehension difficulties7MUCDOTC4 yCyclic vomitinghyporeactivity, seizures13 yYES(11 y)NO(IQ: 106)NOADHD, working memory deficitsNO8FUCDOTC6 yAtaxia confusion, vomit, lethargy22 yNO (\*)NONONONO9FUCDOTC2 yFever, food refusal, irritability5 yYES(6 y)NO (IQ:104)NOAttention and working memory deficitsNO10FUCDOTC14 yComa19 yYES(16 y)YES(IQ: 70)YESAttention and working memory deficitsNO11FUCDOTC(\^)Asymptomatic10 yNO (\*)NONONONO12FUCDOTC(+)Asymptomatic42 yNO (\*)NONONONO13MUCDASS8 yBehavior disorder, ADHD16 yYES(17 y)YES(IQ: 52)YESADHD, working memory deficitsIrritability, aggressiveness14FUCDOTC8 mVomit, food refusal, hyporeactivity10 yNONONO---NO15FUCDOTC3 yHyporeactivity6 yNONOYES---NO16FUCDASS2 dLethargy9 yYES(12 y)NOYESADHDAutistic traits17FUCDOTC3 yLethargy, seizures, coma9 yYES(7 y)YES(IQ: 50)YESAttention and working memory deficitsDisruptive and self-harm behavior18FUCDOTC2 yComa12 yYES(10 y)NO(IQ: 88)NONONO19FUCDASSNSAsymptomatic3 yNO (\*)NO(IQ: 107)NONONO20MMSUDDBT (E2)9 dPoor feeding,lethargy1 yYESNO (IQ:88)NONONO21FMSUDBCKDHB(Ib)10 dPoor feeding, lethargy19 yYESYES(IQ 70--85)NONONO22FMSUDBCKDHB(Ib)9 dPoor feeding,lethargy2 yYESNO(IQ ≥ 85)NOAttention deficitsNO23FMSUDDBT (E2)11 dPoor feeding, lethargy3 mYES(3 y)NO(IQ: 93)NONONO24MMSUDBCKDHB(Ib)7 dPoor feeding, coma, sweet odor smelling13 yYES(8 y)NO(IQ: 89)NOAttention deficitsNO25FMSUDBCKDHB(Ib)7 dPoor feeding,lethargy, sweet odor smelling4 mYES(6 y)NO (IQ:104)NONONO26MMSUDBCKDHB(Ib)7 dPoor feeding,coma19 mYES(1 y)NO (IQ:90)NOAttention and working memory deficitsNO27FMSUDBCKDHB(Ib)NSAsymptomatic28 dNO (\*)(4 y)NO (IQ:108)NONONO28FMSUDBCKDHB(Ib)10 dPoor Feeding,lethargy6 yYESNO(IQ ≥ 85)NOAttention deficitsNO29MBCKDKDeficiencyBCKDK1 mPsychomotor delay, gastrointestinal symptoms, moderate anorexia6 yYESYES (IQ \< 35)YESYESAutism disorder, aggressive disorderADHD: attention deficit hyperactivity; ASL Argininosuccinate Lyase; ASS: Argininosuccinate synthetase, HHH: Hyperornithinemia-Hyperammonemia-Homocitrullinuria, IQ: Intelligence Quotient, IQNPSY: Neuropsychological tests not done but asymptomatic and normal academic and social achievements; MSUD: Maple Syrup Urine Disease, NS: Newborn Screening; OTC: Ornithine transcarbamylase, UCD: Urea Cycle Disorders, (\*)M: male, F: female, d: days; m: months; y: years; - unknown; n.a. not applicable.(\^): diagnosed because of an affected sibling. (+): diagnosed because of an affected son.Table 2Treatment and historical biochemical data records of IEM patients.PatientsDiagnosisTreatmentHistorical data (µmol/L)N° metabolic decompensationsAm (\<50)Gln (330--754)Leu (\<200)MeanMaxMeanMaxMeanMax1OTCL-arginine, L-citrullineProtein-restricted diet02538585734------2OTCNaPBMethylphenidateL-arginine, L-citrullineL-carnitineProtein-restricted diet4532908651387------3OTCL-arginine, L-citrullineProtein-restricted diet1472827211766------4OTCL-citrulline, L-arginineL-carnitineProtein-restricted diet031557271029------5HHHMethylphenidateL-arginine, L-citrullineL-carnitineProtein-restricted diet0612206831060------6ALSL-arginineProtein-restricted diet02845505667------7OTCMethylphenidateL-arginine, L-carnitineProtein-restricted diet237650562835------8OTCL-citrulline, L-carnitineProtein-restricted diet1452478551274------9OTCNaPBL-arginineProtein-restricted diet25918012031792------10OTCNaPBL-arginine, L-citrullineProtein-restricted diet2304858001320------11OTCNaPBL-ArginineProtein-restricted diet04067626796------12OTCL-arginine, L-citrullineProtein-restricted diet036507971085------13ASSNaPBL-arginine, L-carnitineProtein-restricted diet034448041174------14OTCLiver Transplantation: Tacrolimus, Magnogene, Methylprednisolon, Septrin, Usochol, L-citrulline1676698741664------15OTCNaPBL-citrullineProtein-restricted diet151216723889------16ASSNa-Benzoate NaPBL-carnitine, L-arginineProtein-restricted diet6674197601288------17OTCNaPBL-citrulline, L-carnitineProtein-restricted diet1---550------------18OTCL-citrulline, L-carnitineProtein-restricted diet43028810001380------19ASSL-arginine02022400622------20MSUDLow BCAA diet2---------324-21MSUDLow BCAA diet------------414150722MSUDLow BCAA diet5---------278271723MSUDLow BCAA diet1---------302176024MSUDLow BCAA diet5---------239115525MSUDLow BCAA diet1---------211169226MSUDLow BCAA diet1---------16296827MSUDLow BCAA diet0---------9526228MSUDLow BCAA diet5---------378324129BCKDKHigh BCAA dietn.a.---------101197Abbreviations: Am: ammonia, ASL Argininosuccinate Lyase, ASS: Argininosuccinate synthetase, Gln: glutamine, HHH: Hyperornithinemia-Hyperammonemia-Homocitrullinuria, n.a. not applicable, Leu: leucine, MSUD: Maple Syrup Urine Disease, NaPB Sodium phenylbutyrate, OTC: Ornithine transcarbamylase, UCD: Urea Cycle Disorders.

UCD patients (7 males and 12 females) include ornithine transcarbamylase deficiency (OTC deficiency) (14), citrullinemia type I (CTLN1) (3), hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, (HHH syndrome) (1) and argininosuccinate lyase deficiency (ASL deficiency) (1), and five of them (26%) were asymptomatic. All UCD patients were treated with L-Arginine +/− L-Citrulline and all but two followed a protein-restricted diet (0.5--1,3 g/Kg/day). Asymptomatic patients showed mean glutamine levels \<800 µmol/L; while half of symptomatic patients showed mean glutamine levels ≥800 µmol/L. Eight symptomatic patients (42%) were treated with ammonia scavengers, all with sodium phenylbutyrate (NaPB) and one also with sodium benzoate. Patients without scavengers were those with normal ammonia and amino acids in the follow-up metabolic controls. MSUD patients (3 males and 6 females) include mutations in *DBT* (2) and *BCKDHB* (6), one of them asymptomatic. We also included a patient with a genetic diagnose of BCKDK deficiency. MSUD patients followed a low BCAA diet while BCKDK deficiency patient received a high protein diet supplemented with BCAAs. Despite low BCAA diet, mean leucine levels ≥200 µmol/L (normal range in young patients \<200 µmol/L) were observed in 78% of MSUD patients.

From the 29 IEM patients in our cohort, 21 symptomatic patients had a neuropsychological evaluation to detect abnormal executive functions and attention deficits (15 patients) cognitive disabilities (7 patients) and other behavioral disorders (7 patients). Three patients of those who fulfilled ADHD criteria and had poor academic results were treated with psychostimulants (methylphenidate). Neuropsychological evaluation was not performed in healthy control subjects (n = 27) and in asymptomatic patients that achieved successfully both academic and personal life events (n = 8).

Analysis of metabolite levels {#Sec4}
-----------------------------

The 21 principal amino acids and 4 amino acid related-compounds were measured in all plasma samples by ion-exchange chromatography with nynhydrin detection derivatives. Ammonia levels were measured only in OTC patients. Average values for each condition are shown in Table [3](#Tab3){ref-type="table"}.Table 3Summary of biochemical profile.(µmol/L)Control (n = 27)MSUD (n = 9)BCKDK (n = 1)UCD (n = 19)UCD w/sc.(n = 8)UCD w/o sc. (n = 11)Val187.51 ± 34.18201.42 ± 112,82251.40181.50 ± 69.15**138.61** ± **41.30**\*^**£**^219.62 ± 67.80Leu96.29 ± 19.95**233.49** ± **158.75**\*\*115.20101.04 ± 43.2172.89 ± 20.96^££^126.06 ± 43.05Ile50.19 ± 9.82**165.61** ± **103.22**\*\*\*63.4056.26 ± 25.0141.78 ± 13.89^£^69.14 ± 26.19Gly194.83 ± 44.63**320.73** ± **104.39**\*\*\*262.30**245.21** ± **69.42**\*245.03 ± 67.71245.37 ± 75.02Ala305.92 ± 57.86311.02 ± 134.13492.00365.24 ± 148.94407.30 ± 179.26327.86 ± 113.61Ser110.16 ± 24.56**146.30** ± **34.32**\*\*169.80116.05 ± 30.19108.49 ± 21.24122.77 ± 36.34Pro147.81 ± 39.78208.28 ± 87.01273.30157.75 ± 43.21151.69 ± 49.32163.19 ± 39.19Thr111.58 ± 22.07**204.50** ± **92.04**\*\*^**\#\#**^189.10100.32 ± 42.4083.89 ± 34.41114.92 ± 45.26Cys31.13 ± 5.8129.31 ± 7.5935.6033.72 ± 7.7230.59 ± 7.7836.51 ± 6.91Met19.05 ± 3.4622.94 ± 6.2949.10**26.80** ± **7.66**\*\*\*26.86 ± 9.6626.74 ± 5.97\*\*Phe50.23 ± 9.0561.60 ± 22.5095.0046.64 ± 11.98**39.25** ± **7.41**\*^£^53.14 ± 11.69Tyr57.55 ± 15.6576.21 ± 32.77140.4055.33 ± 17.4150.55 ± 19.8859.58 ± 14.73Trp52.78 ± 11.6669.26 ± 25.8199.8053.61 ± 19.1545.65 ± 20.2160.68 ± 16.02Asp5.39 ± 3.366.31 ± 2.304.304.86 ± 2.774.36 ± 1.955.30 ± 3.40Glu25.96 ± 20.88**39.16** ± **18.79**\*22.2028.36 ± 10.7434.39 ± 8.7323.00 ± 9.76Gln414.87 ± 50.12478.48 ± 92.18^\#^579.00**666.14** ± **146.69**\*\*\***753.53** ± **138.38**\*\*\***588.46** ± **108.89**\*\*Asn52.78 ± 8.51**44.27** ± **15.94**\*^**\#\#**^98.80**64.64** ± **19.80**\*58.66 ± 6.5469.94 ± 26.06Hys71.27 ± 9.95**81.39** ± **10.83**\*110.10**90.16** ± **20.03**\*\*\***84.83** ± **8.10**\***94.90** ± **26.29**\*Lys142.68 ± 16.61183.19 ± 46.93281.00143.41 ± 49.44127.75 ± 26.96157.33 ± 61.56Arg54.61 ± 13.8467.67 ± 34.4390.9066.33 ± 27.4165.50 ± 28.6667.07 ± 27.99Orn64.11 ± 21.45**90.80** ± **31.68**\*72.8097.83 ± 90.0075.81 ± 36.94117.40 ± 118.70Tau47.82 ± 21.75**93.97** ± **38.38**\*\*\*^**\#\#**^39.1042.57 ± 19.5645.76 ± 27.9739.73 ± 7.82Cit27.16 ± 7.6228.28 ± 4.6528.70258.55 ± 657.39514.23 ± 919.9131.28 ± 19.42Oh-Pro12.73 ± 6.1115.98 ± 6.9216.5015.48 ± 8.9412.25 ± 4.3518.34 ± 11.13AABA20.70 ± 6.0920.64 ± 4.064.5022.76 ± 11.1519.29 ± 6.4825.84 ± 13.75Ammonia---------35.94 ± 22.3845.33 ± 33.0330.30 ± 11.61Results are presented as mean ± standard deviation. \*Show statistical differences with respect to control, ^\#^with respect to UCD and ^£^with respect to UCD without ammonia scavengers and assessed by Kruskal Wallis test. ^\*/£/\#^P \< 0.05, \*\*^/££/\#\#^p \< 0.01, \*\*\*^/£££/\#\#\#^p \< 0.001. w/sc. with scavenger treatment, w/o sc. without scavenger treatment.

Despite metabolic management, several mean AAs values were out of normal range both in UCD and MSUD groups (Table [3](#Tab3){ref-type="table"}). The mean ammonia level in the UCD group was in the normal range but nitrogen-rich AAs glutamine (p \> 0.0001) and asparagine (p = 0.014) were significantly increased in UCD patients with respect to controls; and as were with glycine (p = 0.014), methionine (p \> 0.0001) and histidine (p = 0.000). As expected, citrulline was only increased in patients with ASS deficiency (p = 0.04). When segregating UCD patients by treatment, patients treated with ammonia scavengers showed specific downregulations of phenylalanine (p = 0.045) and BCAAs (Val p = 0.013; Leu p = 0.003; Ile, p = 0.015) with respect to untreated UCD patients and phenylalanine (p = 0.032) and valine (p = 0.041) also with respect to controls.

BCAAs levels were high in most MSUD patients with leucine (p = 0.01) and isoleucine (p = 0.000) over the control group. glycine (p = 0.000), taurine (p = 0.000), serine (p = 0.004), threonine (p = 0.002), glutamate (p = 0.024), asparagine (p = 0.019), histidine (p = 0.017) and ornithine (p = 0.026) were also significantly elevated in MSUD group with respect to controls. The only BCKDK deficiency patient analyzed showed normal BCAAs, a marked decrease in α-Aminobutyric acid (AABA) and levels above the normal range in other twelve AAs (Table [3](#Tab3){ref-type="table"}).

mRNA and protein expression analysis {#Sec5}
------------------------------------

To ensure the reliability of RT-PCR analysis we set strict sample exclusion criteria (see patients and methods) and as a result, 27 controls, 16 UCD, 7 MSUD, and 1 BCKDK deficiency patients were included in mRNA and further analysis. In addition, outliers were also excluded from the analysis.

A summary of significant differences in mRNA RT-PCR analysis is shown in Table [4](#Tab4){ref-type="table"}. MSUD and UCD groups exhibit significant differences in mRNA gene expression profiles with respect to controls and between them. All genes analyzed in the BCKDK deficiency patient were in the control range. In MSUD patients, *CACNA2D2*, and *MECP2 E1* and *E2* isoforms mRNAs were significantly downregulated (p = 0.007; p = 0.027; p = 0.001 respectively), while *THBS1* mRNA was upregulated (p = 0.047) with respect to controls. In UCD patients, *THBS1* and *LIN28A* mRNA were upregulated with respect to controls (p = 0.031; p = 0.023 respectively). No differences between groups were found for *FMR1*, *IRAK1*, *PTEN*, and *THBS3*.Table 4Gene and BDNF protein expression in peripheral blood.Control (n = 28)MSUD (n = 7)BCKDK (n = 1)UCD (n = 16)UCD w/sc. (n = 8)UCD w/o sc. (n = 8)RQ*ADORA2A*1.03 ± 0.241.13 ± 0.211.3041.11 ± 0.351.30 ± 0.35\*^£^0.93 ± 0.25*CACNA2D2*1.03 ± 0.34**0.55** ± **0.20\*\***^**\#\#**^0.8841.03 ± 0.221.08 ± 0.240.96 ± 0.19*FMR1*1.05 ± 0350.99 ± 0.12---1.21 ± 0.211.18 ± 0.181.23 ± 0.25*IRAK1*1.02 ± 0.171.07 ± 0.171.2181.10 ± 0.241.14 ± 0.241.06 ± 0.26*LIN28A*1.12 ± 0.720.65 ± 0.20^\#\#^0.831**2.42** ± **1.92\***1.82 ± 1.113.03 ± 2.42*MECP2 E1*1.00 ± 0.23**0.79** ± **0.17\***^**\#**^---1.15 ± 0.28**1.23** ± **0.28\***1.04 ± 0.26*MECP2 E2*1.05 ± 0.14**0.79** ± **0.08\*\*\***^**\#\#\#**^1.1501.01 ± 0.180.99 ± 0.201.02 ± 0.16*PTEN*1.04 ± 0.310.98 ± 0.470.8261.42 ± 0.611.24 ± 0.461.60 ± 0.72*THBS1*0.99 ± 0.56**1.73** ± **0.66\***0.713**1.54** ± **0.81\*1.80** ± **0.95\***1.29 ± 0.58*THBS3*1.00 ± 0.211.01 ± 0.061.1401.14 ± 0.221.16 ± 0.231.11 ± 0.22ng/mLBDNF136.20 ± 88.54122.68 ± 68.03---77.64 ± 61.4693.22 ± 85.2467.26 ± 42.01Data are shown as mean ± standard deviation. \*Show statistical differences with respect to control, ^\#^with respect to UCD and ^£^with respect to UCD without ammonia scavengers assessed by Kruskal Wallis test. \*^/£/\#^P \< 0.05. \*\*^/££/\#\#^p \< 0.01. \*\*\*^/£££/\#\#\#^p \< 0.001. w/sc. with scavenger treatment. w/o sc. without scavenger treatment.

When UCD patients were segregated by ammonia scavenger treatment, *ADORA2A* mRNA was significantly increased in those treated with scavengers (n = 8) with respect to control group (p = 0.042) and UCD untreated group (n = 8, p = 0.021). In addition, *MECP2 E1* (p = 0.047) and *THBS1* (p = 0.031), mRNA were significantly increased in those treated with scavengers with respect to control group, but not to untreated UCD patients. Taken together these results suggest that ammonia scavenger treatment might directly increase, *THBS1*, *MECP2 E1*, and *ADORA2A* mRNA expression.

To evaluate the protein expression of the main potential gene biomarkers identified in this study, we performed western blot analysis in purified leukocytes from the same blood samples. We found that protein levels of α2δ2 and MeCP2 in leukocytes from MSUD patients (n = 8) was significantly lower than in controls (n = 5) (p = 0.011, p = 0.048, respectively), corroborating our mRNA results in whole blood (Fig. [1d](#Fig1){ref-type="fig"}). Finally, BDNF protein was measured by ELISA in plasma from the same samples included in the mRNA analysis. BDNF levels were highly variable, even in controls, and although no statistically significant differences were found between groups, there was a tendency of lower levels of BDNF in UCD patients (p = 0.061).Figure 1ROC curves of different neural function biomarker combinations for diagnosis between MSUD or UCD patients and healthy controls. (**a)** UCD; (**b**) MSUD mRNA; (**c**) MSUD protein; (**d**) Representative western blot and densitometric analysis showing significant differences for α2δ2 and MeCP2 in MSUD patients (n = 8) and controls (n = 5). \*p \< 0.05, Mann-Whitney U test.

Spearman correlation between levels of candidate biomarkers and amino acids {#Sec6}
---------------------------------------------------------------------------

We then investigated correlations among potential neural function biomarkers and relevant amino acids using Spearman coefficient of pairwise comparison between samples (Fig. [2](#Fig2){ref-type="fig"}). Correlations were performed between each candidate biomarker for the overall population and relevant statistically significant correlations were identified from the correlation matrix heat map obtained. Spearman coefficient (ρ) of 1 or −1 represents perfect positive or negative correlation respectively.Figure 2Correlations matrix heat maps. Heat map of Spearman correlation between amino acids and potential gene biomarkers performed between each biomarker for the overall population analyzed. 1 is positive correlation. 0 no correlation and −1 is negative correlation. Statistically significant correlations (p \< 0.05) are black boxed.

We found a positive correlation between glutamine levels in plasma and mRNA levels in blood of *THBS1* (ρ = 0.342; p = 0.025) and *THBS3* (ρ = 0.313; p = 0.041), which were also positively correlated between them (ρ = 0.449; p = 0.005). In addition, *THBS1* mRNA positively correlated with *LIN28A* mRNA (ρ = 0.312; p = 0.047), and negatively with BDNF protein levels (ρ = −0.348; p = 0.019); while *THBS3* mRNA positively correlated with mRNA levels of *MECP2 e1* and *e2* isoforms (ρ = 0.353/0.433; p = 0.032/0.007 respectively), *PTEN* (ρ = 0.450; p = 0.006) and *FMR1* (ρ = 0.447; p = 0.033). We also found a significant strong negative correlation between mean historical leucine levels and BCAAs receptor *CACNA2D2* mRNA (ρ = −0.857; p = 0.014); and a significant positive correlation between mean historical leucine levels and taurine (ρ = 0.648; p = 0.043). Consistently, *CACNA2D2* mRNA also had a significant negative correlation with taurine (ρ = −0.420; p = 0.006), isoleucine (ρ = −0.377; p = 0.015) and glutamate (ρ = −0.378; p = 0.015), three AAs that are significantly increased in MSUD patients.

Identification of UCD and MSUD gene biomarker signature {#Sec7}
-------------------------------------------------------

To validate the potential diagnostic and recognition effectiveness of neural function biomarker panels, ROC analysis was applied and the area under the ROC curve (AUC) was calculated for each candidate biomarker. AUC value varies from 0 to 1, where values 0.8 \> AUC \< 0.9 and 0.9 \> AUC \< 1 reflect good and very good biomarker performance respectively.

We first tested sensibility and specificity of candidate biomarkers altered in MSUD or UCD patients with respect to control group, and a summary of relevant potential gene biomarkers is shown in Table [5](#Tab5){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. From BDNF and the 10 genes analyzed in this study only *LIN28A* (AUC = 0.712) and *THBS1* (AUC = 0.707) exhibit fair biomarker accuracy for UCD. On the contrary, in the case of MSUD, good or very good biomarker performance was found for *MECP2 (*AUC *E2* mRNA = 0.942, *E1* mRNA = 0.802, MeCP2 protein = 0.857), *CACNA2D2* (AUC *CACNA2D2* mRNA = 0.865, α2δ2 protein = 0.925) and with less accuracy *THBS1* (AUC mRNA = 0.791). Biomarker specificity and sensitivity are maximal when *MECP2 E2* and *CACNA2D2* mRNA are simultaneously considered (AUC mRNA = 1, protein = 0.95). Taking together, these results suggest that altered α2δ2 and MeCP2 signaling might be involved in the neural function deficits present in MSUD patients.Table 5Area under the curves (AUC) of the biomarker combinations for MSUD and UCD disorders calculated with respect to healthy control group.Biomarker PanelMSUDUCDAUCDesv errorp valueTrendAUCDesv errorp valueTrendLeu0.7860.1110.011↑Ile0.9010.082\<0.001↑Tau0.8890.0550.001↑Glu0.7530.0850.025↑Gly0.9090.048\<0.001↑Gln0.9720.027\<0.001↑*CACNA2D2*0.8650.7200.007↓*LIN28A*0.7160.0920.133↓0.7120.0880.023↑*MECP2 E1*0.8020.0900.027↓*MECP2 E2*0.9420.0450.001↓*THBS1*0.7910.0890.046↑0.7070.0830.031↑*MECP2 E1* + *MECP2 E2*0.9540.0420.001*MECP2 E2* + *CACNA2D2*1.000\<0.001\<0.001*THBS1* + *CACNA2D2*0.9530.0440.003*THBS1* + *LIN28A*0.7310.0900.018α2δ20.9250.0810.013↓MeCP20.8570.1120.042↓α2δ2 + MeCP20.950.060.008

Identification of gene biomarker signature of neural function in IEM patients {#Sec8}
-----------------------------------------------------------------------------

We used the Kruskal Wallis test to identify significant correlations between candidate biomarkers and the presence of neuropsychological symptoms. No significant correlations were found between individual candidate mRNA biomarkers or BDNF and neuropsychological symptoms within MSUD or UCD patients, and the only BCKDK deficiency patient included in the study precludes this type of analysis.

To identify common traits for neuropsychological deficits in IEMs we then analyzed all patient samples as a whole. Low BDNF and threonine levels in plasma, a clinical indicator of protein restriction, have a statistically significant correlation with impaired psychomotor development (BDNF p = 0.035; Thr p = 0.009) (Fig. [3a](#Fig3){ref-type="fig"}). On the other hand, increased *LIN28A* mRNA expression in blood and increased levels of alanine and cysteine in plasma significantly correlated with the presence of other behavioral symptoms (*LIN28A* p = 0.032; Ala p = 0.025; Cys p = 0.027) (Fig. [3c](#Fig3){ref-type="fig"}). Nevertheless, we could not detect LIN28A protein expression in purified leukocytes samples.Figure 3Correlation graphs and ROC curves for candidate biomarkers of neural dysfunction in IEM patients. (**a**) Graphs showing changes in BDNF and threonine in plasma of patients with deficits in psychomotor development and the ROC curves for different biomarker combinations calculated comparing affected with non-affected IEM patients. (**b**) ROC curves for *THBS3* mRNA in blood and AABA in plasma and its combination for the detection of deficits in attention and/or executive functions calculated comparing affected with non-affected IEM patients. (**c**) Graphs showing changes in *LIN28A* mRNA in blood and alanine and cysteine in plasma of patients with other behavioral symptoms and the ROC curves for *LIN28A*. *THBS3* and alanine biomarker combinations calculated comparing affected with non-affected IEM patients.

We then calculated AUC coefficients and a summary of the relevant potential effectiveness of candidate neural function biomarkers is shown in Table [6](#Tab6){ref-type="table"}. For psychomotor delay, the combination of BDNF in plasma and *MECP2 E1* mRNA in whole blood exhibited very good biomarker accuracy (AUC = 0.909). However, accuracy improved when BDNF was combined with serine or threonine in plasma, reaching maximal accuracy (AUC = 1) when a third amino acid between leucine, isoleucine or citrulline was added (Fig. [3a](#Fig3){ref-type="fig"}). Unexpectedly, although no significant differences were found in mRNA in whole blood or in protein expression in leukocytes (data not shown), *THBS3* mRNA exhibited good biomarker performance for executive functions and attention deficits (AUC = 0.857). Biomarker performance increased when *THBS3* was combined with AABA in plasma (AUC = 0.911) (Fig. [3b](#Fig3){ref-type="fig"}). Finally, the combination of *THBS3* and *LIN28A* mRNA exhibited good biomarker performance to detect other behavioral symptoms (AUC = 0.870) in IEM patients, reaching maximal accuracy when was added alanine levels in plasma (AUC = 1) (Fig. [3c](#Fig3){ref-type="fig"}).Table 6Area under the curves (AUC) of the biomarker combinations for neuropsychiatric function in IEM patients calculated comparing affected with non-affected patients.Biomarker PanelPsychomotor DelayExecutive/Attention DeficitsOther Behavioral SymptomsAUCDesv errorp valueTrendAUCDesv errorp valueTrendAUCDesv errorp valueTrendLeu0.7960.0860.017↓0.7530.0980.035↓Ile0.8030.0850.015↓Ala0.7930.1010.023↑Ser0.7570.1100.038↓Thr0.7760.1040.026↓Cys0.7790.0980.031↑Phe0.7630.1160.034↓Lys0.7430.0190.049↓Cit0.8090.1100.013↑0.7540.1370.050↑AABA0.7430.1130.049↓0.7770.0960.021↓*LIN28A*0.7710.1010.045↑*MECP2 E1*0.7800.1250.043↑*MECP2 E2*0.7330.1270.084↑0.7620.1240.053↑*THBS3*0.8570.0910.034↑0.7910.1270.036↑BDNF0.7920.1200.039↓BDNF + Ser0.9640.0410.001BDNF + Thr0.9400.0620.002BDNF + MECP2 E10.9090.0800.007BDNF + (Thr/Ser/Phe) + (Ile/Leu)1.000\>0.0000.001BDNF + (Thr/Ser) + Cit1.000\>0.0000.001*THBS3* + AABA0.9110.0730.015*LIN28A* + *THBS3*0.8700.0850.010*LIN28A* + *THBS3* + Ala1.000\>0.000\>0.000

Taking together, these data point to excessive protein restriction and reduced BDNF levels as hallmarks of psychomotor delay in IEM patients, and point to *THBS3* signaling as involved in executive and attention functions, and *THBS3* with *LIN28A* in behavior control.

Discussion {#Sec9}
==========

UCD and MSUD are intoxication-type IEM while BCKDK deficiency results in BCAAs deficits, and despite correct metabolic management, affected patients frequently suffer psychomotor delay, cognitive, behavioral and psychiatric conditions. To date, early detection and rigorous medical follow-up is the gold standard to minimize neuropsychiatric sequelae^[@CR19],[@CR33],[@CR34]^.

Several studies have assessed amino acid expression in plasma samples of UCD and MSUD patients. However, no biomarkers directly correlated with the neuropsychological features, and the molecular mechanisms involved are still poorly understood^[@CR35],[@CR36]^. To our knowledge, this is the first study where the mRNA expression of genes involved in brain development and synaptic function were assessed in blood from IEM patients and correlated with BDNF and metabolite profiles in plasma.

The main limitation of this study is the reduced sample size (UCD n = 19, MSUD n = 9, and BCKDK deficiency n = 1), as IEMs are rare disorders. The use of blood is also challenging, as biomarker levels in blood can be highly variable and do not directly correlate with levels in brain, especially in diseases with preserved BBB integrity as IEMs. Even with these limitations, we found specific biomarker signatures for MSUD patients and neuropsychiatric dysfunctions in IEMs patients, that pointed to *CACNA2D2*, *THBS1*,*3*, *MECP2*, and *LIN28A* as new potential phenotype modifiers, after further investigation and verification with larger samples.

The first conclusion of this study is that despite metabolic management, most of symptomatic UCD and MSUD patients in our cohort still had glutamine and leucine/isoleucine respectively in the upper limits or above the normal range, and general AAs plasma profile in patients significantly differed from healthy controls.

In the case of MSUD, our data corroborate previous studies conducted in Brazilian and Filipino patients affected with MSUD which reported altered biochemical profile but no correlation between biochemical markers in serum and neuropsychological features^[@CR23],[@CR35]^. However, we did not find a significant reduction in plasma BDNF levels as reported in Brazilian patients^[@CR23]^, which might reflect different metabolic management and nutritional status in the two MSUD cohorts. In our cohort, none of the MSUD patients reported psychomotor delay while it was highly prevalent in the Brazilian cohort (40%).

BDNF levels are highly variable and directly related to food intake and energy metabolism^[@CR37]^ and a reduction in BDNF expression was found in brains of rat offspring after maternal low-protein diet^[@CR38]^. In this sense, 42% of our IEM cohort presented some degree of psychomotor delay, mostly corresponding to UCD patients treated with sodium phenylbutyrate, an ammonia scavenger known to produce a selective reduction in BCAAs^[@CR39]^. We have found a significant inverse correlation between psychomotor delay and levels in plasma of BDNF and essential neutral AAs (mainly threonine, serine, phenylalanine, and BCAAs). These results highlight the necessity of careful metabolic surveillance and diet formulation based on the changing energy requirements of growing patients, as excessive essential neutral amino acid restriction and low BDNF seems to be a hallmark of psychomotor delay.

Nevertheless, we cannot rule out a role for altered BDNF in MSUD neurocognitive and behavioral sequelae, as we have found statistically significant reductions in the expression of *MECP2* mRNA, an epigenetic regulator of BDNF transcription^[@CR40],[@CR41]^. In addition, we have found statistically significant reductions in *CACNA2D2* mRNA in MSUD patients, which was inversely correlated with chronically elevated BCAAs levels. We also found increased levels of *THBS1* in MSUD and UCD patients, which expression was unrelated to BCAAs levels but correlated positively with glutamine and negatively with BDNF plasma levels. Results that are in accordance with published reports showing TSP1 upregulation in mice brains with decreased levels of BDNF^[@CR42]^. TSP1, the protein codified by *THBS1*, is an extracellular matrix (ECM) glycoprotein with antiangiogenic properties that exerts multifunctional effects by binding cell-surface receptors and other proteins in the ECM. TSP1 is up-regulated with injury, chronic pathologies and in response to glucose and AAs, being considered a potent modulator of human diseases^[@CR43]--[@CR45]^.

One of the most important findings of this work is the identification, at the level of mRNA and protein, of a biomarker signature specific at for MSUD that includes α2δ2 (AUC 0.865/0.925) and MeCP2 (AUC 0.942/0.857), as the combination of both yielded the excellent biomarker accuracy (AUC 1/0.95). No specific biomarker signature was found for UCD.

VGCCs auxiliary subunits α2δ1-2, codified by *CACNA2D1-2* genes, regulate calcium ion entry in response to electrical activity in excitable cells^[@CR46],[@CR47]^. In neurons, α2δ1-2 expression modulates neurotransmitter release probability, trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs)^[@CR48],[@CR49]^, and have been involved in learning, memory, anxiety-related behaviors and epilepsy in rats and humans^[@CR50]--[@CR54]^. α2δ1-2 subunits are also essential for the formation and stabilization of new synapses by binding to TSP1-4 secreted by astrocytes^[@CR29],[@CR55]^. It is assumed that BCAAs can induce conformational changes that indirectly affect TSPs binding to α2δ1-2 \[29, 30, 31\]. Moreover, α2δ subunits are the main targets of gabapentinoid drugs (gabapentin and pregabalin), which compete for the same binding site than BCAAs, blocking α2δ synaptogenic functions^[@CR29]^, and biochemically mimicking the action of BCAAs^[@CR56]^.

MeCP2 is an epigenetic regulator that preferentially binds to methylated CpG sites in promoter regions of DNA and is crucial for the correct brain development and the stability control of the neural network in response to activity^[@CR57]--[@CR59]^. Excessive or defective MECP2 function causes neurodevelopmental disorders associated with mental retardation, epilepsy, loss of speech and anxiety, among others^[@CR60]--[@CR65]^.

In addition to the above described, glycine and taurine were significantly increased in MSUD patients, data that is coincidental with previous studies^[@CR23],[@CR35]^, and they stand out for its very good MSUD biomarker performance (AUC glycine 0.909 and AUC taurine 0.889). Glycine and taurine are abundant in brain, where they are involved in several aspects of normal development including neurogenesis, neuronal migration and differentiation^[@CR66],[@CR67]^. Both AAs act as neurotransmitters by binding to glycine receptors, to NMDA receptors (glycine) and to GABA receptors (taurine). In addition, taurine inhibits K^+^-Cl^−^ cotransporter KCC2, modulating Cl^−^ homeostasis, the functionality of inhibitory neurotransmission and neuronal excitability^[@CR68],[@CR69]^. Thus, the increase in glycine and taurine together with the reduced levels of α2δ2 and MeCP2 observed in MSUD patients might reflect an altered synaptogenesis and misbalanced excitatory-inhibitory neural network.

Unexpectedly, although no significant differences were found, *THBS3* mRNA together with AABA in plasma has revealed a good biomarker performance for executive function, attention deficits (AUC 0,911). Reduced AABA in plasma is a frequent consequence of low protein diets and it has been recently associated with depression in older Japanese patients^[@CR70]^. TSP3 is developmentally regulated^[@CR44]^ and few is known about functions. It has been involved in modulating integrin membrane expression and function^[@CR71]^, which is also essential for the formation of correct synaptic structures^[@CR72]^. As TSP3 is a secreted protein, ELISA analysis in plasma would be required to gain insight into their potential biomarker significance.

Finally, increased levels of *LIN28A* mRNA, alanine, and cysteine correlated with behavioral dysfunctions, which include autism spectrum disorder, depression or aggressiveness, and the combination of *THBS3* with *LIN28A* and alanine gave a perfect biomarker signature (AUC 1). LIN28 RNA binding proteins inhibit the biogenesis of let-7 family of miRNAs, a group of miRNAs crucial for embryonic and postnatal development, being at least the 50% of miRNAs present in mature neurons^[@CR73],[@CR74]^. LIN28/let-7 pathway has been involved in controlling cell growth and energy metabolism^[@CR26]^, and regulate dendritic growth and cell survival in response to BDNF^[@CR75]^. Elevated levels of LIN28 and disruption of let-7 biogenesis have been described in animal models and in blood of patients with major depression^[@CR76],[@CR77]^. Previous studies described that elevated levels of cysteine in infants derived in behavioral deficits in adults^[@CR78]^ and plasma levels of alanine have been proposed as a marker of depression severity^[@CR79]^. Taking together, our results are in concordance of what is observed in depression, which is commonly described in patients with inborn errors of metabolism, including UCD and MSUD^[@CR80],[@CR81]^.

Our study, though preliminary, has identified several potential biomarker panels for neural function evaluation, providing a base for future studies. Most importantly, α2δ2 and MeCP2 showed an excellent neural function biomarker signature for MSUD. In addition, *THBS3* mRNA and AABA gave a very good biomarker signature for executive and attention deficits. *THBS3* and *LIN28A* mRNA and alanine showed a perfect biomarker signature for behavioral and mood disorders. Finally, a panel of BDNF and large neutral AAs showed a perfect biomarker signature for psychomotor delay, pointing to excessive protein restriction as potential causatives of psychomotor delay in diet-treated IEM patients. Although these results are very promising, a large number of clinical samples should be collected and the potential biomarkers in each panel quantified at the protein level for the ultimate goal to translate these neural function biomarkers to the clinical practice.

Material and Methods {#Sec10}
====================

Ethical statement {#Sec11}
-----------------

Research Ethics Committee of both hospitals, Sant Joan de Déu and Santiago de Compostela Hospitals, approved the study and informed consent was subscribed by patients and controls (when \>18 years old) or by their parents (when \<18 years old) prior to the collection of data. All methods were performed in accordance with the relevant guidelines and regulations.

Subjects and assessment {#Sec12}
-----------------------

19 patients with a diagnosis of UCDs, 9 patients diagnosed with MSUD, 1 patient with BCKDK (branched-chain ketoacid dehydrogenase kinase deficiency) and 27 healthy age-matched control subjects were recruited for the study at Sant Joan de Déu Hospital in Barcelona and University Hospital of Santiago de Compostela, Spain. Patients were followed in their respective center with the same standardized protocol (Haeberle *et al*. 2012) from the date of diagnosis up to current date. Controls were healthy age-matched individuals with no history of learning difficulties, psychiatric and behavioral problems, who underwent blood analysis in the context of minor surgical interventions.

Inclusion criteria were patients with genetic and/or enzymatic diagnosis of UCDs, MSUD, and BCKDK; asymptomatic and female carriers of OTC deficiency were also included because of abnormal metabolic profile that required a protein-restricted diet. Table [1](#Tab1){ref-type="table"} summarizes the clinical characteristics of the patients. We evaluated the following parameters: age of symptoms onset, psychomotor development and number of decompensations (defined as symptomatic hyperammonemia episode with plasma ammonia greater than 100 μmol/L or amino acid decompensation with leucine greater than 1000 µmol/L). Cognitive functions were assessed by Wechsler Intelligence Scale for Children (WISC)-IV or Kaufman Brief Intelligence Test, Second Edition (K-BIT), considering five severity levels for intellectual disability: Borderline = IQ 70--85, Mild = IQ 55--70; Moderate = IQ 40--55; Severe IQ 25--40; Profound IQ \< 25. Behavioral disorders, attention, and executive functions were assessed by NEPSY-II subtests, Behavior Rating Inventory for Executive Functions (BRIEF) and Conners' Continuous Performance Test II (CPT II). ADHD rating scale --IV (Dupaul) was used for behavioral characterization associated with attention-deficit hyperactivity disorder.

Peripheral blood sample collection {#Sec13}
----------------------------------

Venous blood samples were collected in an anticoagulation EDTA tube after overnight fasting. Biochemical measurements of plasma ammonia, and amino acids were assessed by spectrophotometric technique and ion-exchange chromatography respectively.

Gene expression assays {#Sec14}
----------------------

RNA from 500 µL of whole blood was extracted using miRCURY™ RNA Isolation Kit - Cell & Plant (300110 Exiqon) following supplier instructions. RNA concentration and purity were analyzed in IMPLEN NanoPhotometer® P-Class (Implen). RNA samples (0.5--1 µg) were reverse transcribed to cDNA (High Capacity cDNA Reverse Transcription Kit, 4368814, Applied Biosystems) and Real-Time PCR was performed using TaqMan PCR Assays (4331182, Applied Biosystems) with TaqMan Universal PCR Master Mix (4324018, Applied Biosystems) in the 7900HT Real-Time PCR System (Applied Biosystems). Assays analyzed were: *ADORA2A* (Hs00169123_m1), *CACNA2D2* (Hs01021049_m1), *FMR1* (Hs00924547_m1), *IRAK1* (Hs01018347_m1), *LIN28A* (Hs00702808_s1), *PTEN* (Hs02621230_s1), *MECP2 E1* (Hs01598237_m1), *MECP2 E2* (Hs00172845_m1), *THBS1* (Hs00962908_m1), *THBS3* (Hs00938498_m1). *GUSB* (Hs00939627_m1) and *GAPDH* (Hs99999905_m1) were used as endogenous controls. Data analysis was performed with Expression Suite Software (Life Technologies) and data expressed as Relative Quantification (RQ) normalized with respect to gusb. Sample exclusion criteria were: threshold cycles (Cts) of more than 35, replicates with a standard deviation greater than 0.25 and Cts of *GAPDH* and *GUSB* not consistent. Outliers (identified using interquartile ranges) were removed from the analysis.

BDNF protein detection {#Sec15}
----------------------

The remaining whole blood was centrifuged at 2000 rpm 10 minutes and the plasma obtained was frozen at −80 °C until use. BDNF was measured in duplicates using RayBio® Human BDNF ELISA Kit following supplier instructions.

Western Blot analysis {#Sec16}
---------------------

Leukocytes were obtained from pelleted blood cells after red blood cells lysis with RBC Lysis Buffer (21205, Norgen Biotek corp) following supplier instructions. Proteins were extracted, separated by SDS-page in polyacrylamide gels, and transferred to nitrocellulose membranes (1620112, Bio-Rad). Membranes were blocked for 1 hour at room temperature, primary antibodies were incubated overnight at 4 °C and then with their corresponding secondary HRP-conjugated antibodies for 1 hour (1:5000, Invitrogen). Protein signal was detected with ECL chemiluminiscent system (Amersham, GE Healthcare) in ImageQuant LAS 500 (GE Healthcare). Images were processed with Image Studio Lite 5.2 (LI-COR). Densitometry analysis was performed using gapdh as loading control and ImageJ software (National Institutes of Health). Primary antibodies: rabbit anti- α2δ2 (1:500, Abgent, AP13380C), rabbit anti-MeCP2 (1:1500, Millipore, ABE333), rabbit anti-TSP3 (1:1000, Abgent, AP18972a), rabbit anti-LIN28A (1:200, \#8641, Cell Signaling) and mouse anti-Vinculin (1:750, SCBT, sc-59803). Full length gels are shown in Supplementary info file.

Data analysis {#Sec17}
-------------

SPSS program (IBM SPSS Statistics 24.0) was used to analyze data.

Two tailored non-parametric Kruskal Wallis and Mann-Whitney U tests were used to establish metabolic and gene expression differences between conditions and to correlate candidate biomarkers with clinical variables respectively, as the sample size was not enough to presume normality within the data. Signification values in multiple comparisons were adjusted by Bonferroni correction to reduce Type 1 Error. A bivariate correlation test was used to correlate quantitative variables while Pearson product-moment correlation was used if both variables were qualitative.

To assess biomarker feasibility Receiver Operating Characteristic (ROC) curves and the area under the ROC curve (AUC) were performed. AUC vary from 0 to 1, where values 0.8 ≤ AUC \< 0.9 reflect good and 0.9 ≤ AUC ≤ 1 very good biomarker performance. Statistical significance was set at p values \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001.
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